Methods of synthesizing thyroid hormone analogs and polymorphs thereof
The disclosure describes methods of synthesis of pyridazinone compounds as thyroid hormone analogs and their prodrugs. Preferred methods according to the disclosure allow for large-scale preparation of pyridazinone compounds having high purity. In some embodiments, preferred methods according to the disclosure also allow for the preparation of pyridazinone compounds in better yield than previously used methods for preparing such compounds. Also disclosed are morphic forms of a pyridazinone compound. Further disclosed is a method for treating resistance to thyroid hormone in a subject having at least one TRβ mutation.
1. A compound selected from:
and a salt thereof.
2. The compound of claim 1 , having the following structure:
or a salt thereof.
3. The compound of claim 1 , having the following structure:
or a salt thereof.
4. The compound of claim 1 , having the following structure:
or a salt thereof.
5. The compound of claim 1 , having the following structure:
or a salt thereof.
6. The compound of claim 1 , having the following structure:
or a salt thereof.
7. The compound of claim 1 , having the following structure:
or a salt thereof.
8. The compound of claim 1 , having the following structure:
or a salt thereof.
9. A process comprising:
(a) contacting R 1 MgX or R 1 Li with a compound of Formula (I):
(I) to form a compound of Formula (II):
(II), in which R 1 is isopropyl or isopropenyl, X is halo and R 2 is H or an amine protecting group;
(b) converting the compound of Formula (II) to a compound of Formula (III):
(III) in the presence of a base when R 1 is isopropenyl or in the presence of an oxidizing agent when R 2 is isopropyl;
(c) when present, removing the amine protecting group R 2 of the compound of Formula (III) to form 6-(4-amino-2,6-dichlorophenoxy)-4-isopropylpyridazin-3(2H)-one;
(d) converting 6-(4-amino-2,6-dichlorophenoxy)-4-isopropylpyridazin-3(2H)-one to 2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3,5-di oxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile (“Compound A”); and
(e) forming a morphic form of Compound A (Form I) characterized by an X-ray powder diffraction pattern that includes peaks at about 10.5, 18.7, 22.9, 23.6, and 24.7 degrees 2θ.
10. The process of claim 9 , wherein the compound of Formula (I) is
11. The process of claim 9 , wherein the compound of Formula (II) is selected from:
12. The process of claim 9 , wherein the compound of Formula (III) is